Literature DB >> 5026436

Effect of a magnesium-deficient diet on the striatal content of amines in the dog.

A Barbeau, J M Rojo-Ortega, H M Brecht, J Donaldson, J Minnich, J Genest.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5026436     DOI: 10.1007/BF01928694

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


× No keyword cloud information.
  15 in total

1.  NORMAL SERUM MAGNESIUM LEVELS IN PARKINSON'S DISEASE.

Authors:  R S SCHWAB; A PORYALI; A AMES
Journal:  Neurology       Date:  1964-09       Impact factor: 9.910

2.  EXPERIMENTAL HUMAN MAGNESIUM DEPLETION. I. CLINICAL OBSERVATIONS AND BLOOD CHEMISTRY ALTERATIONS.

Authors:  M E Shils
Journal:  Am J Clin Nutr       Date:  1964-09       Impact factor: 7.045

3.  INFLUENCE OF THE SUBSTANTIA NIGRA ON THE CATECHOLAMINE CONTENT OF THE STRIATUM.

Authors:  L J POIRIER; T L SOURKES
Journal:  Brain       Date:  1965-03       Impact factor: 13.501

4.  Biochemistry of Parkinson's disease.

Authors:  A BARBEAU; G JASMIN; Y DUCHASTEL
Journal:  Neurology       Date:  1963-01       Impact factor: 9.910

5.  The mineral requirements of the dog. III. The magnesium requirement.

Authors:  G E Bunce; K J Jenkins; P H Phillips
Journal:  J Nutr       Date:  1962-01       Impact factor: 4.798

6.  Functional role of the nigro-neostriatal dopamine neurons.

Authors:  N E Andén; A Dahlström; K Fuxe; K Larsson
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1966

7.  Renin activity and norepinephrine, cation, and water contents of cardiovascular tissue of dogs with congestive heart failure, and ascites.

Authors:  K Hayduk; H M Brecht; A Vladutiu; S Simard; J M Rojo-Ortega; L Belleau; R Boucher; J Genest
Journal:  Can J Physiol Pharmacol       Date:  1970-07       Impact factor: 2.273

Review 8.  Dopamine (3-hydroxytyramine) and brain function.

Authors:  O Hornykiewicz
Journal:  Pharmacol Rev       Date:  1966-06       Impact factor: 25.468

9.  Accumulation of dopamine by blood platelets from normal subjects and parkinsonian patients under treatment with L-DOPA.

Authors:  D J Boullin; R A O'Brien
Journal:  Br J Pharmacol       Date:  1970-08       Impact factor: 8.739

10.  Dopamine (3-hydroxytyramine) metabolism in parkinsonism.

Authors:  M Goodall; H Alton
Journal:  J Clin Invest       Date:  1969-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.